The short answer: more joints than most patients expect

ChondroFiller holds CE-mark Class III certification for focal articular cartilage defects across synovial joints — the regulation does not restrict use to a single joint. Meidrix Biomedicals, the German manufacturer, names the knee, hip, shoulder, and ankle as the primary indicated joints; specialist clinical practice extends that list to the elbow, wrist, hand, thumb, and foot.

The consistent thread across every indication is a focal, full-thickness defect in an otherwise stable joint — not generalised degeneration. That distinction matters, and it is stated here once: the sections that follow take it as read.

Evidence depth, however, varies considerably. The knee has the most robust published evidence, drawn from multiple prospective studies spanning 12 to 36 months. The hip carries a meaningful secondary evidence base. The ankle is well-established within joint-preservation pathways. The shoulder, elbow, and small joints sit at earlier stages of the clinical evidence hierarchy — promising, but not yet supported by the same volume of data.

What unifies all of these applications is a single biological logic: the scaffold carries no living cells, making joint anatomy less of a biological barrier than a question of access geometry and evidence maturity. The sections below work through each joint in that order.

The knee: where the evidence is strongest

Published studies give the knee the deepest evidence base of any joint treated with ChondroFiller — and that depth carries weight for any patient researching the treatment, regardless of which joint concerns them.

Multiple prospective cohort studies following patients across 12 to 36 months report consistent functional improvements in validated patient-reported outcome measures. Evidence from these series suggests average gains in IKDC scores of approximately 30 points, sustained across different patient cohorts and follow-up periods — a clinically significant threshold by the standards of the orthopaedic literature. Complication rates across published series are consistently low, and reoperation rates compare favourably against established surgical alternatives: published data indicate a reoperation rate in the region of 3–8%, against figures reaching up to 41% following microfracture and up to 37% following cell-based techniques such as ACI or MACI.

The scaffold's capacity to address focal defects of up to 6 cm² is a practical advantage over microfracture, which is generally suited to smaller lesions. The repair tissue produced has been characterised in published series as hyaline-like rather than fibrocartilaginous — a distinction with implications for long-term mechanical function, since fibrocartilage is structurally inferior to native articular cartilage.

In current UK clinical pathways, ChondroFiller is delivered to the knee as an image-guided outpatient injection, with no surgical admission required. Where microfracture, ACI, or MACI appear in the comparison data above, they represent alternative surgical pathways rather than the service described here.

Hip and ankle: established secondary indications

Hip

The hip represents the most substantive secondary indication in terms of published evidence. Cohort data report Harris Hip Score improvements of approximately 33 points alongside VAS pain reductions of around 6 points — figures that suggest a clinically meaningful change in both function and discomfort, even if patient numbers in these series remain smaller than those accumulated for the knee. That asymmetry in literature volume is worth acknowledging honestly: the hip evidence is real and clinically substantive, but it has not yet reached the same scale as the knee cohorts.

Delivery to the hip involves a specialist image-guided placement technique that temporarily stabilises the joint while the collagen scaffold sets. This is managed at the clinical level and does not alter how patients prepare for or experience the outpatient appointment.

Ankle

The ankle has become well-established as a third indication, most commonly encountered in joint-preservation pathways. Patients often reach this option after an osteochondral injury — a sprain or fracture that has left a focal area of cartilage damage rather than widespread wear. Where that lesion is contained and the surrounding cartilage is healthy, a scaffold-based approach fits neatly within a non-surgical preservation strategy aimed at restoring the joint before more significant degeneration sets in.

For both the hip and ankle, the standard large-joint volume applies — the same as for the knee — and no additional patient preparation is required on account of the joint being treated.

Shoulder, elbow, and small joints: what the evidence currently shows

Moving beyond the knee and hip, the evidence changes substantially — and describing that shift honestly, joint by joint, is more useful than presenting a uniform front.

Shoulder

ChondroFiller can be used in the shoulder for focal cartilage lesions, and it appears in specialist clinical practice in this capacity. Peer-reviewed prospective outcome data for the shoulder remain sparse, however. Clinical feasibility has been demonstrated, but patients considering this joint should understand that the evidence base has not reached the depth seen at the knee.

Elbow

The elbow is in a broadly similar position: used in clinical practice for focal chondral damage, but without published prospective trial data at the time of writing. That gap is worth stating plainly rather than glossing over.

Hand, wrist, and thumb

For small joints, early-stage clinical findings describe encouraging results — pain reportedly halved, grip strength returning, and MRI evidence of increased joint space following treatment. These observations are promising, but they represent early clinical experience rather than structured prospective study data. The distinction matters: such findings indicate that treatment is feasible and may be beneficial, not that the same evidence depth as the knee has been established.

One practical point: dosing reflects anatomy. Large joints receive 2.3 ml of the collagen scaffold; small joints such as those in the hand are treated with a 1 ml formulation — a clinical calibration that does not change the underlying mechanism or meaningfully alter the patient experience.

Temporomandibular joint

The temporomandibular joint has been raised theoretically as a candidate for scaffold-based cartilage repair. No clinical outcome evidence exists in the published literature for this application, placing it firmly in the category of conjecture rather than established practice.

Why one scaffold works across different joints

The scaffold performs the same biochemical role in the ankle as it does in the knee — and the reason is straightforward once the underlying mechanism is clear.

ChondroFiller carries no living cells. It is a Type I collagen matrix: a temporary three-dimensional structure that, once placed, self-gels within a few minutes into a dimensionally stable scaffold. Rather than importing repair cells from an external source, it creates the conditions for the body's own biology to do the work. Mesenchymal stem cells and resident chondrocytes migrate into the matrix from the surrounding synovial tissue and subchondral bone, drawn in by the scaffold's chemotactic properties. As repair tissue — described in published studies as hyaline-like rather than the fibrocartilage produced by some older techniques — forms within the matrix, the collagen structure degrades progressively and is resorbed. What remains is not a permanent foreign material but new tissue built by the patient's own cells.

Because the repair stimulus is endogenous, joint anatomy presents no biological barrier to the mechanism. The scaffold does not require joint-specific cellular populations or conditions peculiar to one anatomical site. What does vary between joints — meaningfully — is access geometry for placement and the depth of published clinical outcome evidence. Those are clinical considerations. The underlying biology is consistent.

Published literature reports more than 19,000 treated cases across joints with no serious complications recorded — a broad safety signal that spans the full range of anatomical indications described in the preceding sections.

Who this treatment is — and is not — for across any joint

In the UK, ChondroFiller is available through a private outpatient pathway only. It carries no NHS funding, is not covered by major private insurers at the time of writing, and is imported under individual prescription on a patient-by-patient basis — practical constraints that apply regardless of which joint is being considered.

Suitability assessment follows the same structure for every joint: MRI to confirm defect geometry and depth, combined with clinical evaluation of the surrounding cartilage and joint environment. The eligibility threshold discussed throughout this article — a focal, contained lesion rather than diffuse degeneration — is not a joint-specific rule but a universal one; the assessment determines whether any given patient's defect profile meets it, wherever that damage sits.

Taken together, the evidence across knee, hip, ankle, shoulder, and small joints points to a consistent pattern: ChondroFiller addresses a biological problem — localised full-thickness cartilage loss where natural repair has stalled — and the anatomical site is secondary to whether the defect profile fits the indication. Patients who meet that profile in any of the covered joints have a clinical rationale for taking the next step. Those with widespread joint degeneration do not, regardless of which joint is involved.

An eligibility assessment at amsk.co.uk can clarify which category applies based on imaging and clinical findings.